Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

Multi-detector row computed tomography predicts malignancy of IPMNs

A clinical research article to be published on August 28, 2009 in the World Journal of Gastroenterology addresses the role of multi-detector row computed tomography (MDCT) in predicting malignancy of IPMNs preoperatively. The research team led by Prof. Wang DB from Ruijin Hospital of Shanghai Jiao Tong University School of Medicine recruited a total of 20 patients with pathologically-confirmed IPMNs in their study. Axial MDCT images combined with CT angiography (CTA) and multiplanar volume or curved reformations (MPVR or CR) were preoperatively acquired.

17 Sep 2009

Standard liver volume formula for Chinese adults published

Living donor liver transplantation (LDLT) has been used to alleviate the shortage of available liver donors. Accurate estimation of the standard liver volume (SLV) of the living donor and recipient is crucial. Scholars of different countries established several SLV formulae from clinical data, but which formula was the most accurate for Chinese adults has remained unclear.

17 Sep 2009

Diagnocure reports third-quarter fiscal 2009 results

DiagnoCure Inc. (TSX: CUR), a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services, announced revenue of $396,468 and a net loss of $4,034,364 or $0.09 per share for the third quarter ending July 31, 2009.

17 Sep 2009

Amgen to present its four Phase 3 clinical trial results

Amgen today announced it will present detailed data from four Phase 3 studies as well as other data at the ECCO 15 - ESMO 34 European Multidisciplinary Congress, September 20 - 24, 2009 in Berlin, Germany.

16 Sep 2009

Sudden Cardiac Arrest Foundation launches second video awareness contest on YouTube

To celebrate National Sudden Cardiac Arrest Awareness Month in October, the Sudden Cardiac Arrest Foundation today announced the launch of its second 'You Can Save a Life(TM)' video awareness contest on YouTube.

16 Sep 2009

Immune response at tumour site predicts cancer progression in colorectal cancer patients

The immune reaction at tumour site determines cancer evolution and clinical outcome in patients with colorectal cancer, regardless of the local extent and spread of the tumour, according to the findings of Jérôme Galon, INSERM Research Director, Paris, and co-workers.

16 Sep 2009

Hispanic/Latino Americans have a unique cancer risk profile, says report

The latest edition of Cancer Facts & Figures for Hispanics/Latinos reports that Hispanic/Latino Americans -the largest, fastest-growing, and youngest minority in the United States-have a unique cancer risk profile that requires a targeted approach to cancer prevention.

15 Sep 2009

Third-quarter fiscal 2009 results announced by DiagnoCure

15 Sep 2009

Given Imaging'c PillCam COLON 2 video capsule and system receives the CE mark for sale in Europe

Given Imaging Ltd. (NASDAQ: GIVN) today announced encouraging results from a trial that validated new features of the company's second-generation PillCam® Colon video capsule and system. The Company also announced that it has obtained the CE mark for the sale of PillCam COLON 2 in Europe.

14 Sep 2009

Trabedersen granted orphan drug designation from both FDA And EMEA for treating pancreatic carcinoma

The biopharmaceutical company Antisense Pharma GmbH has announced today that it has received orphan drug designation from both the European Medicines Agency EMEA and the US Food and Drug Administration FDA for its investigational drug trabedersen in the treatment of pancreatic carcinoma.

14 Sep 2009

Sanofi-aventis and Regeneron Pharmaceuticals discontinue Phase 3 trial of aflibercept

Sanofi-aventis and Regeneron Pharmaceuticals, Inc. today announced the discontinuation of the Phase 3 trial that evaluated aflibercept (VEGF Trap) plus gemcitabine versus placebo plus gemcitabine for the first-line treatment of metastatic pancreatic cancer (VANILLA), based on the recommendations by an Independent Data Monitoring Committee (IDMC).

14 Sep 2009

Body mass in younger and older adulthood linked to prostate cancer risks

A team of scientists led by researcher Brenda Hernandez, Ph.D., M.P.H.-an assistant professor at the University of Hawai'i at Mānoa's Cancer Research Center of Hawai'i-has reported that body mass in younger and older adulthood, and weight gain between these life periods, may influence a man's risk for prostate cancer. This risk varies among different ethnic groups, according to findings reported in a study published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

14 Sep 2009

Oral NKTR-118 has low risk for mediating significant drug-drug interactions

Nektar Therapeutics presented clinical study data today demonstrating that the oral tablet formulation of NKTR-118 has favorable systemic bioavailability and a low risk for mediating significant drug-drug interactions.

14 Sep 2009

Abstracts on Merck Serono oncology treatments to be presented at ECCO and ESMO

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, continues to drive the global effort to ensure patients receive personalized cancer therapies. A total of 17 abstracts concerning Merck Serono oncology treatments will be presented at the joint 15th Congress of the European Cancer Organisation (ECCO) and 34th Congress of the European Society for Medical Oncology (ESMO), to be held in Berlin from 20-24 September 2009.

11 Sep 2009

Gastroenterologists applaud President's call for screening tests coverage

Gastrointestinal specialists from the American College of Gastroenterology applaud President Obama's call to cover preventive screening tests, such as breast cancer exams and colonoscopy. In his health care speech to a joint session of Congress last night, the President argued that "there's no reason we shouldn't be catching diseases like breast cancer and colon cancer before they get worse. That makes sense."

11 Sep 2009

GI Company's Phase II study demonstrates safety of rhITF oral spray formulation

Published today, as an original investigation, in the peer-reviewed Journal of Clinical Oncology, are statistically significant Phase II clinical results of The GI Company's lead clinical compound, rhITF (recombinant human Intestinal Trefoil Factor) oral spray. The article is titled, "A Phase II, Randomized, Double-blind, Placebo-Controlled Study of rhITF Oral Spray for Prevention of Oral Mucositis in Colorectal Cancer Patients Receiving 5-Fluorouracil-based Chemotherapy."

10 Sep 2009

Laureate Pharma and Neoprobe sign manufacturing agreement

Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, and Laureate Pharma, Inc., a full-service biopharmaceutical development and protein production company, today announced that they have entered into a Biopharmaceutical Development and Manufacturing Agreement.

9 Sep 2009

DOR's Phase 1/2 clinical trial for prevention of radiation enteritis receives NIH grant

DOR BioPharma, Inc. (OTC Bulletin Board: DORB) (DOR or the Company), a late-stage biotechnology company, announced today that the National Institutes of Health (NIH) has awarded DOR a Small Business Innovation Research (SBIR) grant to support the conduct of a Phase 1/2 clinical trial evaluating DOR201, a time-release formulation of oral beclomethasone dipropionate (oral BDP), for the prevention of acute radiation enteritis.

8 Sep 2009

Screening rates for colorectal cancer are lower in safety net health system, study reveals

Colorectal cancer screening rates are much lower among those in a safety net health system compared to the national average, and the number one predictor of screening is a combination of regular visits and insurance access.

8 Sep 2009

Two ongoing Phase 2 clinical trials of CPX-351 to be showcased

Celator Pharmaceuticals today announced that Scott Jackson, chief executive officer, is scheduled to present at the Thomas Weisel Partners 2009 Healthcare Conference in Boston.

4 Sep 2009